Healthcare provider profile · identity verified

Mandee Stull, FNP-C

Nurse Practitioner · STUARTS DRAFT, VA · NPI 1023676798

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	162	76
Lisinopril	Lisinopril	158	69
Amlodipine Besylate	Amlodipine Besylate	140	65
Losartan Potassium	Losartan Potassium	126	64
Omeprazole	Omeprazole	113	53
Levothyroxine Sodium	Levothyroxine Sodium	102	47
Metoprolol Succinate	Metoprolol Succinate	76	32
Albuterol Sulfate Hfa	Albuterol Sulfate	73	37
Metformin Hcl	Metformin Hcl	70	30
Prednisone	Prednisone	64	52
Pantoprazole Sodium	Pantoprazole Sodium	58	32
Pravastatin Sodium	Pravastatin Sodium	56	20
Metoprolol Tartrate	Metoprolol Tartrate	54	21
Furosemide	Furosemide	51	25
Sertraline Hcl	Sertraline Hcl	50	26
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	45	39
Escitalopram Oxalate	Escitalopram Oxalate	45	14
Hydrochlorothiazide	Hydrochlorothiazide	43	23
Rosuvastatin Calcium	Rosuvastatin Calcium	42	20
Gabapentin	Gabapentin	41	21
Allopurinol	Allopurinol	38	16
Simvastatin	Simvastatin	38	21
Doxycycline Hyclate	Doxycycline Hyclate	37	33
Famotidine	Famotidine	37	17
Metformin Hcl Er	Metformin Hcl	37	18
Eliquis	Apixaban	36	12
Tamsulosin Hcl	Tamsulosin Hcl	36	16
Carvedilol	Carvedilol	34	20
Trazodone Hcl	Trazodone Hcl	33	17
Tramadol Hcl	Tramadol Hcl	30	19
Warfarin Sodium	Warfarin Sodium	30	17
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	29	24
Montelukast Sodium	Montelukast Sodium	27	suppressed
Ondansetron Odt	Ondansetron	27	19
Spironolactone	Spironolactone	27	15
Baclofen	Baclofen	26	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	11
Diclofenac Sodium	Diclofenac Sodium	24	16
Indapamide	Indapamide	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	12
Fluticasone Propionate	Fluticasone Propionate	21	17
Glimepiride	Glimepiride	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	20	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	18
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Myrbetriq	Mirabegron	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Alendronate Sodium	Alendronate Sodium	18	suppressed
Duloxetine Hcl	Duloxetine Hcl	18	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Ozempic	Semaglutide	18	suppressed
Bupropion Xl	Bupropion Hcl	17	suppressed
Glipizide	Glipizide	17	suppressed
Potassium Chloride	Potassium Chloride	17	suppressed
Symbicort	Budesonide/Formoterol Fumarate	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	12
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Meloxicam	Meloxicam	15	suppressed
Valsartan	Valsartan	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Glipizide Er	Glipizide	14	suppressed
Synthroid	Levothyroxine Sodium	14	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Colchicine	Colchicine	12	suppressed
Finasteride	Finasteride	12	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error